Sign In
Buy VERU
$2.25
-0.100 (-4.26%)
At Close: Jun 03, 2026
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
01:36pm, Monday, 11'th Apr 2022 PennyStocks
What you need to know about trading penny stocks on April 11th
The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informat
Why Is Veru (VERU) Stock Up 200% Today?
12:34pm, Monday, 11'th Apr 2022
Veru (VERU) stock is taking off on Monday as investors react to recent clinical trial news about the company's Covid-19 treatment. The post Why Is Veru (VERU) Stock Up 200% Today?
Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized Patients
12:10pm, Monday, 11'th Apr 2022
Veru Inc (NASDAQ: VERU) has announced positive efficacy and safety results from a planned interim analysis of Phase 3 COVID-19 trial evaluating oral sabizabulin 9 mg versus placebo. The trial inclu
Why Veru Stock Is Surging Today
10:50am, Monday, 11'th Apr 2022
Veru Inc (NASDAQ: VERU) shares are trading significantly higher Monday after the company reported its novel COVID-19 drug candidate reduced deaths by 55% in hospitalized patients in an interim analys
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
10:30am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
-- Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized COVID-19 Patients at High Risk for ARDS Be Stopped Early Due t
Pharma Stock Surging on Upbeat Covid-19 Treatment Data
09:27am, Monday, 11'th Apr 2022
Another company could be joining the ranks of Covid-19 treatment producers: Veru Inc (NASDAQ:VERU).
Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference
01:30pm, Friday, 04'th Mar 2022 GlobeNewswire Inc.
MIAMI, March 04, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers
Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022
08:30am, Tuesday, 01'st Mar 2022
MIAMI, March 01, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers,
The Behavior Of Veru Inc. (VERU) Stock Is Not As Predictable As You Think
03:30pm, Friday, 25'th Feb 2022 Stocks Register
Veru Inc. (NASDAQ:VERU) concluded the trading at $5.77 on Thursday, February 24 with a rise of 8.46% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $5.32 and 5Y monthly beta was reading 0.50 with its price kept floating in the range … The Behavior Of Veru Inc. (VERU) Stock Is Not As Predictable As You Think Read More »
Veru Inc. (VERU) Has A Bright Growth Prospects For 2022
08:00pm, Monday, 21'st Feb 2022 Marketing Sentinel
Veru Inc. (NASDAQ:VERU) has a beta value of 0.52 and has seen 0.94 million shares traded in the last trading session. The company, currently valued at $442.57M, closed the last trade at $5.69 per share which meant it lost -$0.32 on the day or -5.32% during that session. The VERU stock price is -224.96% off Veru Inc. (VERU) Has A Bright Growth Prospects For 2022 Read More »
Veru updates Phase 1b/2 data for sabizabulin in prostate cancer
02:25pm, Thursday, 17'th Feb 2022 Seeking Alpha
Veru (VERU) highlighted the long-term efficacy of its experimental cancer therapy, sabizabulin, after announcing the additional data from its Phase 1b/2 clinical study in…
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
01:30pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,
Warning: VERU is at high risk of performing badly
09:59am, Tuesday, 15'th Feb 2022 Seeking Alpha
Veru to further advance late-stage trial for COVID-19 therapy after data analysis
06:06pm, Monday, 14'th Feb 2022 Seeking Alpha
Veru <> announced on Monday that an independent panel recommended the continuation of its global Phase 3 COVID-19 registration study for oral sabizabulin as previously…
Data Committee Recommends Veru''s COVID-19 Trial To Continue Unmodified
03:13pm, Monday, 14'th Feb 2022 Benzinga
The Independent Data Monitoring Committee (IDMC) has conducted a planned conditional power analysis of the first 75 randomized patients in Veru Inc''s (NASDAQ: VERU ) Phase 3 trial of sabizabulin. The trial included hospitalized patients with moderate to severe COVID-19 infection at high risk for acute respiratory distress syndrome … Full story available on Benzinga.com
